HeimPRE • NASDAQ
add
Prenetics Global Ltd
4,42 $
Eftir lokun(5,20%)+0,23
4,65 $
Lokað: 22. nóv., 20:00:00 GMT-5 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
4,61 $
Dagbil
4,42 $ - 4,42 $
Árabil
2,85 $ - 7,84 $
Markaðsvirði
54,00 m. USD
Meðalmagn
11,72 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(USD) | jún. 2024info | Breyting á/á |
---|---|---|
Tekjur | 5,94 m. | 4,32% |
Rekstrarkostnaður | 14,38 m. | 0,52% |
Nettótekjur | -10,72 m. | 50,83% |
Hagnaðarhlutfall | -180,46 | 52,87% |
Hagnaður á hvern hlut | — | — |
EBITDA | -9,51 m. | 13,59% |
Virkt skatthlutfall | 0,79% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
(USD) | jún. 2024info | Breyting á/á |
---|---|---|
Reiðufé og skammtímafjárfestingar | 63,89 m. | -67,46% |
Heildareignir | 233,31 m. | -16,93% |
Heildarskuldir | 42,30 m. | -30,22% |
Eigið fé alls | 191,00 m. | — |
Útistandandi hlutabréf | 12,22 m. | — |
Eiginfjárgengi | 0,30 | — |
Arðsemi eigna | -11,12% | — |
Ávöxtun eigin fjár | -13,33% | — |
Peningaflæði
Breyting á handbæru fé
(USD) | jún. 2024info | Breyting á/á |
---|---|---|
Nettótekjur | -10,72 m. | 50,83% |
Handbært fé frá rekstri | — | — |
Reiðufé frá fjárfestingum | — | — |
Reiðufé frá fjármögnun | — | — |
Breyting á handbæru fé | — | — |
Frjálst peningaflæði | — | — |
Um
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Stofnsett
2014
Vefsvæði
Starfsfólk
322